We are live on ! Find out more
BSA

Braun Stacey Associates Portfolio holdings

AUM $3.01B
1-Year Est. Return 47.79%
This Fund
S&P 500
This Quarter Est. Return
+2.93%
1 Year Est. Return
+47.79%
3 Year Est. Return
+184.24%
5 Year Est. Return
+273.21%
10 Year Est. Return
+1,255.9%
AUM
$3.01B
AUM Growth
-$77.5M
Cap. Flow
-$45.6M
Cap. Flow %
-1.52%
Top 10 Hldgs %
32.99%
Holding
119
New
6
Increased
40
Reduced
57
Closed
7

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$28.4M
2
TDY icon
Teledyne Technologies
TDY
+$17.1M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.5M
4
IQV icon
IQVIA
IQV
+$13.6M
5
R icon
Ryder
R
+$12M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$25.9M
2
NOW icon
ServiceNow
NOW
+$22.6M
3
BSX icon
Boston Scientific
BSX
+$12.1M
4
MU icon
Micron Technology
MU
+$11.7M
5
WDC icon
Western Digital
WDC
+$9.36M

Sector Composition

Rank Sector Weight
1 Technology 30.15%
2 Financials 13.03%
3 Communication Services 10.89%
4 Industrials 10.55%
5 Healthcare 9.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLF icon
101
State Street Financial Select Sector SPDR ETF
XLF
$55.1B
$504K 0.02%
10,201
-213
-2% -$11.1K
IWD icon
102
iShares Russell 1000 Value ETF
IWD
$81.3B
$420K 0.01%
1,965
+867
+79% +$190K
IWF icon
103
iShares Russell 1000 Growth ETF
IWF
$123B
$320K 0.01%
3,000
-192
-6% -$21.8K
VONV icon
104
Vanguard Russell 1000 Value ETF
VONV
$20.2B
$303K 0.01%
3,230
-903
-22% -$86.8K
XLU icon
105
State Street Utilities Select Sector SPDR ETF
XLU
$24B
$287K 0.01%
6,252
– –
XLK icon
106
State Street Technology Select Sector SPDR ETF
XLK
$116B
$270K 0.01%
2,034
-1,631
-45% -$230K
TRGP icon
107
Targa Resources
TRGP
$61.3B
$251K 0.01%
1,000
-1,050
-51% -$228K
VTI icon
108
Vanguard Total Stock Market ETF
VTI
$654B
$227K 0.01%
707
-20
-3% -$6.71K
XLY icon
109
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$21.3B
$217K 0.01%
1,989
+20
+1% +$2.34K
SCHD icon
110
Schwab US Dividend Equity ETF
SCHD
$100B
$203K 0.01%
+6,606
New +$200K
CORT icon
111
Corcept Therapeutics
CORT
$10.4B
– –
-264,297
Closed -$9.2M
CTAS icon
112
Cintas
CTAS
$81.3B
– –
-4,828
Closed -$908K
IWM icon
113
iShares Russell 2000 ETF
IWM
$81.2B
– –
-817
Closed -$201K
NBIX icon
114
Neurocrine Biosciences
NBIX
$17.5B
– –
-182,262
Closed -$25.9M
NOW icon
115
ServiceNow
NOW
$94.8B
– –
-147,225
Closed -$22.6M
TSLA icon
116
Tesla
TSLA
$1.2T
– –
-460
Closed -$207K
VO icon
117
Vanguard Mid-Cap ETF
VO
$106B
– –
-4,620
Closed -$335K
1 2 3 4
5

Similar funds

CI
Conning Inc Hartford, Connecticut $3.01B AUM 16.23% 1-Year Est. Return
BGDI
BW Gestao de Investimentos Sao Paulo, Brazil $3.01B AUM 27.43% 1-Year Est. Return
Members Trust
Members Trust Tampa, Florida $3.01B AUM 10.24% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
VVP
Venture Visionary Partners Sylvania, Ohio $3B AUM 24.41% 1-Year Est. Return
KIA
KCM Investment Advisors Greenbrae, California $3.01B AUM 21.97% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TAM
Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return

Braun Stacey Associates's Q1 2026 Portfolio in Review

As of Q1 2026, Braun Stacey Associates held 119 positions worth $3.01B, down 2.5% from $3.09B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Braun Stacey Associates's Q1 2026 filing shows 6 new, 40 increased, 57 reduced and 7 closed positions. Its largest new stake was Merck: 246,022 shares worth $29.6M. The largest sale was Neurocrine Biosciences, an estimated $25.9M.

By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 32% a quarter earlier, followed by Financials and Communication Services.

  • Braun Stacey Associates's largest Q1 2026 buy was Merck: 246,022 shares worth $29.6M.
  • Braun Stacey Associates added most to Ascendis Pharma A/S in Q1 2026, an estimated $2.67M increase.
  • Braun Stacey Associates's biggest Q1 2026 reduction was Boston Scientific, cutting an estimated $12.1M.
  • Braun Stacey Associates fully exited Neurocrine Biosciences in Q1 2026, selling an estimated $25.9M.
  • Braun Stacey Associates's ten largest holdings make up 33% of its $3.01B portfolio in Q1 2026.
  • Braun Stacey Associates opened 6 new positions and closed 7 in Q1 2026.
  • Braun Stacey Associates's portfolio value fell 2.5% quarter-over-quarter to $3.01B.

Based on Braun Stacey Associates's 13F filing for Q1 2026, filed 22 Apr 2026.